New US Customer Orders Nexstim NBS 6 System
3 juli, 08:00
3 juli, 08:00
Press release, Helsinki, 3 July 2025 at 9 AM (EEST)
New US Customer Orders Nexstim NBS 6 System
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a hospital located in Western United States.
The NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-cleared for the treatment of major depressive disorder (MDD), as well as CE-marked for the treatment of MDD and chronic unilateral neuropathic pain. Nexstim’s systems are based on the company’s unique navigated transcranial magnetic stimulation (nTMS) technology.
Mikko Karvinen, CEO of Nexstim, comments: “From R&D efforts to sales of our current products and supporting our customers and business partners, the Nexstim team worked very hard towards achieving our key strategic objectives during the first half of the year. We are excited for the rest of the year and determined to continue the efforts.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
AttachmentsNexstim Plc_Press release_US order_03072025_FINAL.pdf
3 juli, 08:00
Press release, Helsinki, 3 July 2025 at 9 AM (EEST)
New US Customer Orders Nexstim NBS 6 System
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a hospital located in Western United States.
The NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-cleared for the treatment of major depressive disorder (MDD), as well as CE-marked for the treatment of MDD and chronic unilateral neuropathic pain. Nexstim’s systems are based on the company’s unique navigated transcranial magnetic stimulation (nTMS) technology.
Mikko Karvinen, CEO of Nexstim, comments: “From R&D efforts to sales of our current products and supporting our customers and business partners, the Nexstim team worked very hard towards achieving our key strategic objectives during the first half of the year. We are excited for the rest of the year and determined to continue the efforts.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
AttachmentsNexstim Plc_Press release_US order_03072025_FINAL.pdf
Börsen idag
Börsen idag
Börsen idag
Börsen idag
1 DAG %
Senast
Loomis
4 juli, 17:52
Defensiva bolag mot strömmen – OMXS30 föll 0,7%
Atrium Ljungberg
4 juli, 15:07
Fastighetsfredag: Nedåt på rapporter
OMX Stockholm 30
1 DAG %
Senast
2 512,53